OHP-002 Cost of treatment analysis of biosimilar and innovator infliximab in a tertiary level hospital

BackgroundThe availability of biosimilar infliximab (IFX) has been postulated to offer cost savings compared with innovator IFX, which could lead to patients being switched between drugs.PurposeTo analyse demographic characteristics and pathologies of patients treated with IFX and to evaluate the co...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	European journal of hospital pharmacy. Science and practice 2017-03, Vol.24 (Suppl 1), p.A179-A180
Hauptverfasser:	García, C Mondelo, Bargiela, N Fernández, Queiruga, M García, Cortizas, B Feal, Vázquez, M Lestón, Arufe, V Giménez, Herranz, MI Martín
Format:	Artikel
Sprache:	eng
Schlagworte:	Biological products Cost control Drug dosages Expenditures Inflammatory bowel disease Monoclonal antibodies Psoriasis Rheumatoid arthritis TNF inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!